Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | September 15, 2026 | September 15, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | February 02, 2024 | February 06, 2024 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,184 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,000 · Balance 8,184 |
REGENERON PHARMACEUTICALS, INC.
Report date February 02, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,693 |
Ending reported balance
After 2024-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-02 · Exercise / conversion · Acquired 400 · Balance 23,974 Row 2 · 2024-02-02 · Tax withholding · Disposed 281 · Balance 23,693 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $378.98 · Expires 2027-12-12 | Direct | 11,787 |
Reported balance
After 2024-02-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-02 · Exercise / conversion · Disposed 400 · Balance 11,787 F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 270 |
Reported balance
Holding disclosure · report date 2024-02-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 270 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 15, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,000 | $72.13 | $72,130.00 |
DisclosureSEC source: 0001061983-26-000095 · form4.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,184 Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 23:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,000 | $74.66 | $74,660.00 |
DisclosureSEC source: 0001061983-26-000093 · form4.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,184 Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 4,301 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0001061983-26-000056 · form4.xml · derivative · entry 2 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,301 Underlying: Common Stock · 4,301 shares Expires 2036-05-26 Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000056 · form4.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,184 Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:56 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010859 · ownership.xml · derivative · entry 2 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:56 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010859 · ownership.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 00:30 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0000950170-25-107543 · ownership.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2035-08-10 F1 · derivative.exercise_date: Stock options vest in 36 equal monthly installments starting one month after grant date of August 11, 2025. Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,880 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014356 · form4.xml · derivative · entry 2 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2035-05-13 F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014356 · form4.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,333 F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 13:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 25,538 | $0.00 Strike: $42.21 | $0.00 |
DisclosureSEC source: 0001127602-25-003989 · form4.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,538 Underlying: Common Stock · 25,538 shares Expires 2035-02-12 F1 · kind: Initial grant to new director. Stock Options vest monthly over 3-years from the date of grant. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-24-000053 · edgardoc.xml · derivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,787 Underlying: Common Stock · 400 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 281 | $956.65 | $268,818.65 |
DisclosureSEC source: 0001968202-24-000053 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,693 Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 400 | $378.98 | $151,592.00 |
DisclosureSEC source: 0001968202-24-000053 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-24-000045 · edgardoc.xml · derivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,187 Underlying: Common Stock · 400 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 282 | $953.42 | $268,864.44 |
DisclosureSEC source: 0001968202-24-000045 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,574 Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 400 | $378.98 | $151,592.00 |
DisclosureSEC source: 0001968202-24-000045 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-24-000040 · edgardoc.xml · derivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,587 Underlying: Common Stock · 500 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 352 | $951.26 | $334,843.52 |
DisclosureSEC source: 0001968202-24-000040 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,456 Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $378.98 | $189,490.00 |
DisclosureSEC source: 0001968202-24-000040 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-24-000040 · edgardoc.xml · derivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,087 Underlying: Common Stock · 1,100 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 776 | $948.50 | $736,036.00 |
DisclosureSEC source: 0001968202-24-000040 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,308 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,100 | $378.98 | $416,878.00 |
DisclosureSEC source: 0001968202-24-000040 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-24-000036 · edgardoc.xml · derivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,187 Underlying: Common Stock · 500 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 354 | $932.34 | $330,048.36 |
DisclosureSEC source: 0001968202-24-000036 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,984 Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $378.98 | $189,490.00 |
DisclosureSEC source: 0001968202-24-000036 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-24-000034 · edgardoc.xml · derivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,687 Underlying: Common Stock · 800 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 568 | $928.18 | $527,206.24 |
DisclosureSEC source: 0001968202-24-000034 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,838 Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 800 | $378.98 | $303,184.00 |
DisclosureSEC source: 0001968202-24-000034 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-24-000031 · edgardoc.xml · derivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,487 Underlying: Common Stock · 500 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 342 | $917.05 | $313,631.10 |
DisclosureSEC source: 0001968202-24-000031 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,606 Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $378.98 | $189,490.00 |
DisclosureSEC source: 0001968202-24-000031 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001883850-24-000005 · edgardoc.xml · derivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,987 Underlying: Common Stock · 1,100 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 688 | $912.30 | $627,662.40 |
DisclosureSEC source: 0001883850-24-000005 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,448 Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,100 | $378.98 | $416,878.00 |
DisclosureSEC source: 0001883850-24-000005 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 650 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001883850-24-000005 · edgardoc.xml · derivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,087 Underlying: Common Stock · 650 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 421 | $888.34 | $373,991.14 |
DisclosureSEC source: 0001883850-24-000005 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,036 Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 650 | $378.98 | $246,337.00 |
DisclosureSEC source: 0001883850-24-000005 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 850 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001883850-23-000108 · edgardoc.xml · derivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,737 Underlying: Common Stock · 850 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 612 | $884.88 | $541,546.56 |
DisclosureSEC source: 0001883850-23-000108 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,807 Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 850 | $378.98 | $322,133.00 |
DisclosureSEC source: 0001883850-23-000108 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 750 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001883850-23-000108 · edgardoc.xml · derivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,587 Underlying: Common Stock · 750 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 542 | $872.21 | $472,737.82 |
DisclosureSEC source: 0001883850-23-000108 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,569 Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 750 | $378.98 | $284,235.00 |
DisclosureSEC source: 0001883850-23-000108 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001883850-23-000100 · edgardoc.xml · derivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,337 Underlying: Common Stock · 1,000 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 723 | $871.12 | $629,819.76 |
DisclosureSEC source: 0001883850-23-000100 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,361 Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $378.98 | $378,980.00 |
DisclosureSEC source: 0001883850-23-000100 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,381 | $856.71 | $5,466,666.51 |
DisclosureSEC source: 0001883850-23-000100 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,084 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,552 | $844.09 | $2,154,117.68 |
DisclosureSEC source: 0001968202-23-000051 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,465 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 669 | $844.09 | $564,696.21 |
DisclosureSEC source: 0001968202-23-000051 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,017 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,013 | $843.79 | $854,759.27 |
DisclosureSEC source: 0001968202-23-000051 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,686 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.